NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- GX Foundation opens its global headquarters in Hong Kong
- China's success in development empowers Global South
- Study explains why Chang'e 6 moon soil is unexpectedly sticky
- Rare Sapria himalayana once again enters blooming period in Yunnan
- Shenzhou XXII to launch with full cargo load
- Students practice restoring Yuan Dynasty mural details at Shanxi University
